Pemetrexed safety and pharmacokinetics in patients with third-space fluid by Dickgreber, Nicolas J et al.
Highlights of This Issue 2697
SPECIAL FEATURES
2699 Epigenetic Markers in Rectal Cancer
Lei Xu, Brian G. Czito, and 
Christopher G. Willett
See article p. 2811
2702 Estrogen Receptor Mutations and
Changes in Downstream Gene
Expression and Signaling
Ines Barone, Lauren Brusco, 
and Suzanne A.W. Fuqua
2709 Integration of Epidermal Growth
Factor Receptor Inhibitors with
Preoperative Chemoradiation
Annelies Debucquoy, Jean-Pascal Machiels,
William H. McBride, and Karin Haustermans
2715 Differentiation Therapy Exerts
Antitumor Effects on Stem-like
Glioma Cells
Benito Campos, Feng Wan, 
Mohammad Farhadi, Aurélie Ernst, 
Felix Zeppernick, Katrin E. Tagscherer,
Rezvan Ahmadi, Jennifer Lohr, 
Christine Dictus, Georg Gdynia, 
Stephanie E. Combs, Violaine Goidts,
Burkhard M. Helmke, Volker Eckstein,
Wilfried Roth, Philipp Beckhove, 
Peter Lichter, Andreas Unterberg, 
Bernhard Radlwimmer, 
and Christel Herold-Mende 
2729 Graft-versus-Leukemia Antigen
CML66 Elicits Coordinated B-Cell
and T-Cell Immunity after Donor
Lymphocyte 
Wandi Zhang, Jaewon Choi, Wanyong Zeng,
Shelby A. Rogers, Edwin P. Alyea, 
James G. Rheinwald, Christine M. Canning,
Vladimir Brusic, Tetsuro Sasada, 
Ellis L. Reinherz, Jerome Ritz, 








May 15, 2010 • Volume 16 • Number 10
2740 Activation of -Catenin by Hypoxia
in Hepatocellular Carcinoma
Contributes to Enhanced Metastatic
Potential and Poor Prognosis 
Liang Liu, Xiao-Dong Zhu, Wen-Quan Wang,
Yuan Shen, Yi Qin, Zheng-Gang Ren, 
Hui-Chuan Sun, and Zhao-You Tang
2751 DNMT3L Is a Novel Marker and Is
Essential for the Growth of Human
Embryonal Carcinoma
Kahori Minami, Tokuhiro Chano, 
Takahiro Kawakami, Hiroshi Ushida, 
Ryoji Kushima, Hidetoshi Okabe, 
Yusaku Okada, and Keisei Okamoto
2760 Efficacy, Biodistribution, and
Pharmacokinetics of CD22-Targeted
Pegylated Liposomal Doxorubicin
in a B-cell Non–Hodgkin’s
Lymphoma Xenograft Mouse Model
Joseph M. Tuscano, Shiloh M. Martin,
Yunpeng Ma, William Zamboni, 
and Robert T. O’Donnell
2769 Anti-GD3 Chimeric sFv-CD28/T-Cell
Receptor  Designer T Cells for
Treatment of Metastatic Melanoma
and Other Neuroectodermal Tumors
Agnes S.Y. Lo, Qiangzhong Ma, 
David L. Liu, and Richard P. Junghans
2781 Two Distinct Mechanisms of
Augmented Antitumor Activity by
Modulation of Immunostimulatory/
Inhibitory Signals 
Jun Mitsui, Hiroyoshi Nishikawa, 
Daisuke Muraoka, Linan Wang, 
Takuro Noguchi, Eiichi Sato, 
Satoshi Kondo, James P. Allison, 
Shimon Sakaguchi, Lloyd J. Old, 
Takuma Kato, and Hiroshi Shiku
2792 New Molecular and Biological
Mechanism of Antitumor Activities
of KW-2478, a Novel Nonansamycin
Heat Shock Protein 90 Inhibitor, in
Multiple Myeloma Cells
Takayuki Nakashima, Toshihiko Ishii,
Hisashi Tagaya, Toshihiro Seike, 
Hiroshi Nakagawa, Yutaka Kanda, 
Shiro Akinaga, Shiro Soga, 
and Yukimasa Shiotsu
CANCER THERAPY: PRECLINICAL
The Journal of Clinical and Translational Research
The Journal of Clinical and Translational Research iii www.aacrjournals.org
CANCER THERAPY: CLINICAL
2852 Functional Proteomic Analysis of
Advanced Serous Ovarian Cancer
Using Reverse Phase Protein Array:
TGF- Pathway Signaling Indicates
Response to Primary Chemotherapy
Mark S. Carey, Roshan Agarwal, Blake Gilks,
Kenneth Swenerton, Steve Kalloger, 
Jennifer Santos, Zhenlin Ju, Yiling Lu, 
Fan Zhang, Kevin R. Coombes, Dianne Miller,
David Huntsman, Gordon B. Mills, 
and Bryan T. Hennessy
2861 Preoperative CTLA-4 Blockade:
Tolerability and Immune
Monitoring in the Setting of a
Presurgical Clinical Trial
Bradley C. Carthon, Jedd D. Wolchok, 
Jianda Yuan, Ashish Kamat, 
Derek S. Ng Tang, Jingjing Sun, 
Geoffrey Ku, Patricia Troncoso, 
Christopher J. Logothetis, James P. Allison,
and Padmanee Sharma
2872 Pemetrexed Safety and
Pharmacokinetics in Patients with
Third-Space Fluid
Nicolas J. Dickgreber, Jens Benn Sorensen,
Luis G. Paz-Ares, Tine Kjestrup Schytte, 
Jane E. Latz, Karen B. Schneck, Zheng Yuan,
and José Miguel Sanchez-Torres
2881 Phase I Open-Label Study of
Continuous Treatment with BIBF
1120, a Triple Angiokinase
Inhibitor, and Pemetrexed in
Pretreated Non–Small Cell Lung
Cancer Patients
Peter M. Ellis, Rolf Kaiser, Yihua Zhao, 






Gene Expression Profiles Associated
with Outcome
Jessica M. Grunda, John Fiveash, 
Cheryl A. Palmer, Alan Cantor, 
Hassan M. Fathallah-Shaykh, L. Burt Nabors,
and Martin R. Johnson
2899 Intraindividual Comparison of
Selective Arterial versus Venous
68Ga-DOTATOC PET/CT in Patients
with Gastroenteropancreatic
Neuroendocrine Tumors
Clemens Kratochwil, Frederik L. Giesel,
Ruben López-Benítez, Nadine Schimpfky,
Kirsten Kunze, Michael Eisenhut, 
Hans-Ulrich Kauczor, and Uwe Haberkorn
iv Clinical Cancer Research
IMAGING, DIAGNOSIS, PROGNOSIS
2803 Tumor Metabolism and Blood 
Flow as Assessed by Positron
Emission Tomography Varies by
Tumor Subtype in Locally Advanced
Breast Cancer
Jennifer M. Specht, Brenda F. Kurland, 
Susan K. Montgomery, Lisa K. Dunnwald,
Robert K. Doot, Julie R. Gralow, 
Georgina K. Ellis, Hannah M. Linden, 
Robert B. Livingston, Kimberly H. Allison,
Erin K. Schubert, and David A. Mankoff
2811 Identification of a Quantitative
MINT Locus Methylation Profile
Predicting Local Regional
Recurrence of Rectal Cancer
Michiel F.G. de Maat, Cornelis J.H. van de Velde,
Anne Benard, Hein Putter, Hans Morreau, 
J. Han J.M. van Krieken, 
Elma Meershoek Klein-Kranenbarg, 
Eelco J. de Graaf, Rob A.E.M. Tollenaar, 
and Dave S.B. Hoon
See commentary p. 2699
2819 Susceptibility Loci Associated 
with Prostate Cancer Progression
and Mortality
David J. Gallagher, Joseph Vijai, 
Angel M. Cronin, Jasmine Bhatia, 
Andrew J. Vickers, Mia M. Gaudet, 
Samson Fine, Victor Reuter, Howard I. Scher,
Christer Halldén, Ana Dutra-Clarke, 
Robert J. Klein, Peter T. Scardino, 
James A. Eastham, Hans Lilja, 
Tomas Kirchhoff, and Kenneth Offit
2833 Near IR Heptamethine Cyanine
Dye–Mediated Cancer Imaging
Xiaojian Yang, Chunmeng Shi, Rong Tong,
Weiping Qian, Haiyen E. Zhau, 
Ruoxiang Wang, Guodong Zhu, 
Jianjun Cheng, Vincent W. Yang, 
Tianmin Cheng, Maged Henary, 
Lucjan Strekowski, and Leland W.K. Chung
2845 Association of SPINK1 Expression
and TMPRSS2:ERG Fusion with
Prognosis in Endocrine-Treated
Prostate Cancer
Katri A. Leinonen, Teemu T. Tolonen, 
Hazel Bracken, Ulf-Håkan Stenman, 
Teuvo L.J. Tammela, Outi R. Saramäki, 
and Tapio Visakorpi
2906 Phase II Study on the Addition 
of ASA404 (Vadimezan; 
5,6-Dimethylxanthenone-4-Acetic
Acid) to Docetaxel in CRMPC
Roberto Pili, Mark A. Rosenthal, 
Paul N. Mainwaring, Guy Van Hazel, 
Sandy Srinivas, Robert Dreicer, Sanjay Goel,
Joseph Leach, Shirley Wong, 
and Peter Clingan
2915 Differences in MicroRNA Expression
Profiles of Adrenocortical 
Tumors – Letter
Zsófia Tömböl, Peter M. Szabó, Attila Patócs,
Károly Rácz, and Peter Igaz
LETTERS TO THE EDITOR
The Journal of Clinical and Translational Research v www.aacrjournals.org
2915 MicroRNA Microarray Analysis of
Human Adrenocortical Tumors
Identifies miR-195 and miR-483-5p
as Predictors of Poor Prognosis in
Adrenocortical Cancer – Response
Patsy S.H. Soon, Lyndal J. Tacon, 
Roderick J. Clifton-Bligh, 
Bruce G. Robinson, Stan B. Sidhu, 
Peter R. Campbell, Anthony J. Gill, 
Christopher P. Bambach, Mark S. Sywak, 
Michael W. Yeh, and Steven G. Wong
2917 Correction: Lack of Correlation
between Epidermal Growth Factor





Drug-induced differentiation is considered a promising approach to
eradicate stem-like tumor cells in glioma. In their study, Campos and
colleagues analyzed potential effects of a retinoid-based differentiation
therapy on the angiogenic behavior of stem-like glioma cells. The
representative intravital fluorescence image on the cover shows vessel
activity in the proximity of a retinoid-treated, green fluorescent
protein–transfected tumor spheroid, placed on a cerebral mouse cortex.
In vivo differentiated stem-like glioma cells showed only moderate signs
of angiogenic activity and absent neovascularization, suggesting that
differentiation therapy impairs their angiogenic behavior. For details, 
see the article by Campos and colleagues on page 2715 of this issue.
